0001078782-16-002133.txt : 20160105 0001078782-16-002133.hdr.sgml : 20160105 20160105173657 ACCESSION NUMBER: 0001078782-16-002133 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160101 FILED AS OF DATE: 20160105 DATE AS OF CHANGE: 20160105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VOLITIONRX LTD CENTRAL INDEX KEY: 0000093314 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 911949078 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 SCOTTS RD #24-05 SHAW CENTRE CITY: SINGAPORE STATE: U0 ZIP: 228208 BUSINESS PHONE: 1 (646) 650-1351 MAIL ADDRESS: STREET 1: 1 SCOTTS RD #24-05 SHAW CENTRE CITY: SINGAPORE STATE: U0 ZIP: 228208 FORMER COMPANY: FORMER CONFORMED NAME: STANDARD CAPITAL CORP DATE OF NAME CHANGE: 19990812 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TERRELL JASON BRADLEY MD CENTRAL INDEX KEY: 0001567531 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36833 FILM NUMBER: 161323992 MAIL ADDRESS: STREET 1: P.O. BOX 3018 CITY: MARBLE FALLS STATE: TX ZIP: 78654 3 1 primary_doc.xml PRIMARY DOCUMENT X0206 3 2016-01-01 0 0000093314 VOLITIONRX LTD VNRX 0001567531 TERRELL JASON BRADLEY MD 1 SCOTTS RD #24-05 SHAW CENTRE SINGAPORE U0 228208 SINGAPORE 0 1 0 0 Chief Medical Officer Common Stock 61364 D Warrant (Right to Buy) 2.47 Common Stock 25000 D Warrant (Right to Buy) 2.47 Common Stock 25000 D Warrant (Right to Buy) 2.47 Common Stock 50000 D Warrant (Right to Buy) 2.47 Common Stock 50000 D Stock Option (Right to Buy) 2.5 2015-02-18 2019-02-18 Common Stock 12500 D Stock Option (Right to Buy) 3 2016-02-18 2020-02-18 Common Stock 12500 D A total of 25,000 Common Stock Warrants are to vest, if earned, upon the Company signing a second clinical trial agreement in the United States. The Common Stock Warrants shall expire three years from the vesting date. A total of 25,000 Common Stock Warrants are to vest, if earned, upon the Company signing an agreement with a laboratory/group certified through the CLIA for the use of the Company's proprietary screening kits and devices for the detection of certain diseases in humans in the United States. The Common Stock Warrants shall expire three years from the vesting date. A total of 50,000 Common Stock Warrants are to vest, if earned, on the date the Company receives approval from the FDA for the sale and distribution in the United States of its first proprietary screening kit or device for the detection of a certain disease. The Common Stock Warrants shall expire three years from the vesting date. A total of 50,000 Common Stock Warrants are to vest, if earned, on the date the Company receives approval from the FDA for the sale and distribution in the United States of its second proprietary screening kit or device for the detection of a certain disease. The Common Stock Warrants shall expire three years from the vesting date. A total of 25,000 Stock Options were granted on August 18, 2014 under the Company's 2011 Equity Incentive Plan. The Options vest in two equal installments at 6 months and at 18 months from the date of grant, and expire four years from the vesting date. The reporting person has served in a part-time capacity as the Chief Medical Officer and Head of U.S. Operations of VolitionRx Limited since March 2013, and also concurrently held positions between January 2013 and October 2015 with other publicly-held companies. The reporting person transitioned to full-time, employment status as the Chief Medical Officer and Head of U.S. Operations, and entered into an Employment Agreement, with VolitionRx Limited, effective January 1, 2016 (the indicated "Date of Event Requiring Statement"). /s/ Jason Terrell, M.D. 2016-01-01